Regeneron Pharmaceuticals Inc (NASDAQ:REGN) received a $447.00 price target from equities researchers at Piper Jaffray Cos. in a note issued to investors on Thursday. The firm presently has a a “hold” rating on the biopharmaceutical company’s stock. Piper Jaffray Cos.’s target price would indicate a potential upside of 19.69% from the stock’s previous close.

A number of other research firms have also recently issued reports on REGN. Vetr upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $472.09 target price for the company in a research note on Tuesday, August 2nd. Robert W. Baird cut shares of Regeneron Pharmaceuticals from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $505.00 to $448.00 in a research note on Friday, August 5th. Canaccord Genuity reiterated a “hold” rating and issued a $450.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, August 5th. Cowen and Company reiterated a “hold” rating and issued a $430.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, August 5th. Finally, Roth Capital reiterated a “buy” rating and issued a $520.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, August 5th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $480.09.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 1.281% during mid-day trading on Thursday, hitting $378.255. 383,894 shares of the stock traded hands. Regeneron Pharmaceuticals has a one year low of $329.09 and a one year high of $592.59. The stock has a market capitalization of $39.58 billion, a PE ratio of 59.010 and a beta of 1.31. The company has a 50 day moving average price of $399.99 and a 200-day moving average price of $392.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.17. The company earned $1.21 billion during the quarter, compared to analysts’ expectations of $1.24 billion. Regeneron Pharmaceuticals had a net margin of 15.65% and a return on equity of 23.77%. Regeneron Pharmaceuticals’s quarterly revenue was up 21.4% compared to the same quarter last year. During the same quarter last year, the company posted $2.89 EPS. Equities analysts anticipate that Regeneron Pharmaceuticals will post $11.02 earnings per share for the current fiscal year.

In other news, Director Joseph L. Goldstein sold 2,125 shares of the company’s stock in a transaction on Friday, July 29th. The shares were sold at an average price of $425.00, for a total value of $903,125.00. Following the completion of the sale, the director now owns 15,125 shares in the company, valued at approximately $6,428,125. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 10.40% of the stock is currently owned by insiders.

Several hedge funds have recently bought and sold shares of REGN. NN Investment Partners Holdings N.V. purchased a new stake in Regeneron Pharmaceuticals during the first quarter valued at about $1,477,000. Bessemer Group Inc. raised its stake in Regeneron Pharmaceuticals by 45.4% in the first quarter. Bessemer Group Inc. now owns 548 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 171 shares during the last quarter. Aviva PLC raised its stake in Regeneron Pharmaceuticals by 3.0% in the first quarter. Aviva PLC now owns 44,809 shares of the biopharmaceutical company’s stock valued at $16,151,000 after buying an additional 1,297 shares during the last quarter. Ithaka Group LLC raised its stake in Regeneron Pharmaceuticals by 1.6% in the first quarter. Ithaka Group LLC now owns 64,541 shares of the biopharmaceutical company’s stock valued at $23,263,000 after buying an additional 1,007 shares during the last quarter. Finally, Meiji Yasuda Asset Management Co Ltd. raised its stake in Regeneron Pharmaceuticals by 1.2% in the first quarter. Meiji Yasuda Asset Management Co Ltd. now owns 852 shares of the biopharmaceutical company’s stock valued at $307,000 after buying an additional 10 shares during the last quarter. Hedge funds and other institutional investors own 68.16% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.